FIGURE

FIGURE 2

ID

ZDB-FIG-231228-131

Publication

Valencia-Sama et al., 2023 - SHP2 inhibition with TNO155 increases efficacy and overcomes resistance of ALK inhibitors in neuroblastoma

Other Figures

All Figure Page

Back to All Figure Page

FIGURE 2

TNO155 synergizes with ALK-TKIs in ALK-mutant neuroblastoma cells. Cell viability (alamarBlue) analysis (A) and determination of drug interaction (B) in neuroblastoma cells with ALK wild-type (WT) or mutant (MUT) status treated with DMSO control, TNO155, ceritinib, or TNO155 plus ceritinib for 72 hours. C, Western immunoblots of Kelly and SH-SY5Y cells treated with TNO155 (1 µmol/L), ceritinib (0.1 µmol/L), or combination for 24 hours. Cell viability analysis (D) and determination of drug interaction (E) in neuroblastoma cells treated with TNO155, lorlatinib, or TNO155 plus lorlatinib for 72 hours. F, Western immunoblots of Kelly and SH-SY5Y cells treated with TNO155 (1 µmol/L), lorlatinib (1 µmol/L), or combination for 24 hours. Drug concentrations are shown in Supplementary Table S1A. Synergy was calculated using the EOB model. EOB scores > 0, synergistic. *, P < 0.05; **, P < 0.01; ***, P < 0.001; n.s., not significant.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Cancer Res Commun